Activity Overview
This educational activity is an archive of the live presentation held on May 30, 2026.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This
educational activity is directed toward oncologists, NPs/PAs, nurses,
pharmacists, and other HCPs involved in the management of breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Implement best practices for molecular testing in HR+/HER2-negative metastatic breast cancer, including selection of tissue vs liquid biopsy and indications for repeat testing at progression.
- Differentiate between available and emerging oral SERDs based on pivotal trial data, real-world evidence, and patient-specific factors to guide treatment selection in ESR1-mutant disease.
- Evaluate the role of oral SERD monotherapy versus combination regimens in the post-CDK4/6 inhibitor setting, balancing efficacy with tolerability.
- Develop individualized treatment strategies for patients with co-occurring ESR1 and PIK3CA mutations, integrating evidence for oral SERDs and PI3K/AKT pathway inhibitors.
Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and
Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio
The University of Texas MD Anderson Cancer Center
San Antonio, TX
Disclosures: Grant/Research Support: Eisai; Consultant: AstraZeneca, Genentech, Gilead, Lilly, Menarini, Pfizer; Speaker: AstraZeneca, Daiichi Sankyo, Gilead
Antonio Giordano, MD, PhD
Assistant Professor of Medicine and Senior Physician
Harvard Medical School
Clinical Director, Center for Cancer Therapeutic Innovation (Early
Drug Development)
Medical Director, Breast Cancer Pathway
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Advisor, Consultant, Fee for Service Recipient: AstraZeneca, Araris, Axis, Curio, DAVA, Eli Lilly, Guardant Health, MDEducation, Novartis, Pfizer, Totus Medicine; Grant/Research Funding: Cardiff Oncology
Nadia Harbeck, MD, PhD
Chair, Conservative Oncology
Director, Breast Center
LMU University Hospital
Munich, Germany
Disclosures: Advisor, Consultant, Fee for Service Recipient: Daiichi-Sankyo, IQVIA, Novartis, Pfzier, Roche/Genentech; Speaker Bureau: Amgen, AstraZeneca, Daiichi-Sankyo, Exact Sciences, Lilly, Menarini-Stemline, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Viatris, Zuelligpharma; Grant/Research Funding (paid to institution): AstraZeneca, Lilly, MSD, Novartis, Pfizer, Roche/Genentech; Stock/Ownership: WSG (Women’s Cancer Study Group)
Sarah Sammons, MD
Co-Chief of Breast Oncology
University of Maryland
Marlene and Stewart Greenebaum
Comprehensive Cancer Center
Baltimore, MD
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Daiichi Sankyo, Gilead Sciences, Lilly, Novartis, Pfizer, Relay Therapeutics, Seagen; Grant/Research Funding: Alterome, AstraZeneca, BioNTech, Daiichi Sankyo, Iambic, Lilly, Relay Therapeutics
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
